New treatment options in castration-resistant prostate cancer.

Published

Journal Article

Most of the updates in the 2015 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer center on the systemic therapy front, with a host of newer agents in the mix. At the NCCN 20th Annual Conference, Dr. Andrew J. Armstrong discussed some of the key developments in metastatic castration-resistant and castration-sensitive prostate cancer, particularly the conflicting results on repurposing docetaxel in castration-sensitive disease, the specific population who may experience greater survival benefit from immunotherapy in castration-resistant disease, updated data on the use of androgen receptor and biosynthesis inhibitors, and the emerging role of AR-V7 (androgen-receptor splice variant 7 messenger RNA) as a biomarker of treatment response.

Full Text

Duke Authors

Cited Authors

  • Armstrong, AJ

Published Date

  • May 2015

Published In

Volume / Issue

  • 13 / 5 Suppl

Start / End Page

  • 690 - 693

PubMed ID

  • 25995432

Pubmed Central ID

  • 25995432

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

International Standard Serial Number (ISSN)

  • 1540-1405

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2015.0205

Language

  • eng